BioNTech, GSK top pharma performers in October; Bristol, Amgen biggest laggards
$BNTX.US$ was the best performing large pharma/biotech company in October, with a return of ~11.5%.
The German company continues to benefit from sales of its COVID-19 vaccine. October marked the first full month booster shots were available in the U.S., and indications are the uptake is significant.
On Oct. 29, the FDA also granted authorization to BioNTech and its partner $PFE.US$ for vaccinations in children between the ages of 5 and 11.
Pfizer eked out a small gain of 0.6% in the month.
In mid October, a report surfaced that there was keen interest in its consumer health business. Later in the month, GSK raised its 2021 earnings guidance.
A highlight for Lilly in the month was its announcement it began a rolling submission of its Alzheimer's candidate donanemab.
Late in the month, Bristol hit a 52-week low even though it beat Q3 2021 earnings estimates. Shares are down ~7.9% year to date.
$AMGN.US$ came in second place losing 3.2%.
Shares hit a 52-week low on Oct. 12 and almost fell below $200 per share.
While Gilead boosted its FY 2021 financial outlook, Cantor Fitzgerald lowered its price target due to a likely delay in the launch of a cancer drug.
Rounding out the top five worst performers were Pfizer and $NVS.US$ with gains of, respectively, 0.6% and 1.6%.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
wild horse : GILD forward-looking EPS over $10 through 2022. Stock price will rebound from recent low.
Q3 2021 = $2.65 (not too Shabby)
Remdesivir will continue to provide solid growth and there is no competition from another drug. JMHO
Teddy Willson wild horse : Wait GILD got an EPS over 10 and the stock is still depressed? Shows me that Gen Z/ Millennials might get taken to the woodshed and the old timers will dance again.
Teddy Willson : Long abbv amen mrk and pfe for dividends and capital appriciation. Solid companies with good futures.
baby boomers : BMY,AMGN,GILD are all solid buys but maybe a little better near the end of the year when tax selling and mutual funds abandon their losers for 2021.If you like to throw the long ball sometimes maybe TEVA
Harper lee : Have a feeling the FDA will delay approving Moderna for kids and adolescents. BNTX will control this market